MedicalResearch.com Interview with: [caption id="attachment_59375" align="alignleft" width="130"] Dr. Roth[/caption] Bryan Roth, MD, PhD Michael Hooker Distinguished Professor Pharmacology Director, NIMH Psychoactive Drug Screening Program Eshelman School of Pharmacy [caption id="attachment_59376" align="alignleft" width="125"] Gavin Schmitz[/caption] Gavin P. Schmitz Department of Pharmacology University of North Carolina at Chapel Hill School of Medicine Chapel Hill, North Carolina   Department of Pharmacology, School of Medicine University of North Carolina at Chapel Hill Chapel Hill, North Carolina MedicalResearch.com:  What is the background for this study?  What are the main findings?  Response: There is undoubtably a lot of enthusiasm for psychedelics as therapeutic tools right now both in research and more broadly; however, there are still so many questions that need to be answered. It has been established that SNPs are clinically relevant when considering how patients may respond to various atypical antipsychotic drugs, so we wanted to see if they also could impact psychedelic assisted treatment strategies. What we found is that genetics do matter; namely, our results indicate that patients with different genes will react differently to psychedelics.